Core Viewpoint - Vivos Therapeutics, Inc. has entered into a definitive agreement for the immediate exercise of outstanding warrants, which will generate approximately $4.64 million in gross proceeds for the company [1][4]. Group 1: Financial Details - The company will exercise warrants to purchase up to 1,982,356 shares at a reduced exercise price of $2.34 per share, down from original prices ranging from $3.83 to $5.05 [1]. - In exchange for the cash exercise of existing warrants, Vivos will issue new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share [3]. - The offering is expected to close on or about January 20, 2026, subject to customary closing conditions [4]. Group 2: Company Overview - Vivos Therapeutics focuses on developing and commercializing innovative diagnostic and treatment methods for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [7]. - The company’s devices are FDA-cleared for treating OSA in both adults and children, with its Complete Airway Repositioning and Expansion (CARE) devices being the only FDA 510(k) cleared technology for severe OSA in adults [7]. - OSA affects over 1 billion people globally, with 90% undiagnosed, highlighting a significant market opportunity for Vivos [8]. Group 3: Strategic Intent - Vivos aims to empower healthcare providers to address the complex needs of OSA patients through innovative technology, education, and collaborations with sleep healthcare providers [9]. - The company promotes its treatment approach, known as The Vivos Method, which is a nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [10].

Core Insights - Vivos Therapeutics, Inc. is expanding its operations with the grand opening of a new sleep testing and treatment center in Auburn Hills, Michigan, as part of its national expansion strategy to address obstructive sleep apnea (OSA) [1][3] - The new center operates under a capital-efficient affiliation model, allowing Vivos to partner with existing sleep clinics rather than solely relying on acquisitions, which enhances scalability and reduces capital intensity [2][4] - Vivos aims to provide innovative diagnostic and therapeutic solutions for OSA patients, leveraging its proprietary FDA-cleared products to improve patient outcomes and generate higher revenue for affiliated practices [3][4] Company Overview - Vivos Therapeutics focuses on developing and commercializing diagnostic and treatment methods for sleep-related breathing disorders, particularly OSA, with FDA-cleared devices for both adults and children [6][8] - The company emphasizes a non-invasive and non-pharmaceutical approach to treating OSA, known as The Vivos Method, which aims to address the root causes of the disorder rather than relying on traditional treatments like CPAP [9][7] Market Context - OSA affects over 1 billion people globally, with a significant portion undiagnosed, highlighting a substantial market opportunity for Vivos to provide effective treatments [7] - The sleep testing industry has faced pricing pressures, leading to closures and consolidations, which Vivos aims to counteract by offering differentiated treatment options through strategic affiliations [4][5]

Core Insights - Vivos Therapeutics, Inc. is a medical device and healthcare services company focused on diagnosing and treating sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [1][3] - The company will participate in a fireside chat to discuss its strategic business model pivot, operational execution, market opportunities, competitive environment, and growth strategies [2] Company Overview - Vivos Therapeutics, founded in 2016 and based in Littleton, Colorado, specializes in innovative diagnostic and treatment methods for breathing and sleep issues related to dentofacial abnormalities [3][5] - The company's devices are FDA-cleared for treating all severity levels of OSA in adults and moderate-to-severe OSA in children aged 6 to 17 [3] - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for severe OSA treatment in adults and the first for moderate to severe OSA in children [3] Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [4] - Traditional OSA treatments, such as CPAP, often fail to address the root causes of the disorder, indicating a significant market opportunity for innovative solutions [4] Treatment Approach - Vivos employs a proprietary treatment method known as The Vivos Method, which is nonsurgical, noninvasive, and nonpharmaceutical, aiming to provide effective solutions for OSA patients [6]

Core Insights - Vivos Therapeutics reported a 78% sequential revenue growth in Q3 2025, driven by the first full quarter of operations from the Sleep Center of Nevada acquisition, with a year-over-year revenue increase of 76% [2][4] - The strategic pivot from a dental distribution model to direct affiliations and acquisitions of medical sleep practices is yielding positive results, as evidenced by the revenue contributions from the Sleep Center of Nevada [2][4] - The company is optimistic about growth potential in the Las Vegas area and plans to expand its model into other major markets [2][6] Financial Performance - Q3 2025 revenue reached $6.8 million, up from $3.9 million in Q3 2024, while revenue for the nine months ended September 30, 2025, was $13.6 million compared to $11.3 million in the same period of 2024 [4][23] - Gross profit for Q3 2025 was $3.9 million, reflecting an increase from $2.3 million in Q3 2024, with gross margins at 58% compared to 60% in the previous year [4][11] - Operating expenses rose to $8.7 million in Q3 2025, a 74% increase from $5.0 million in Q3 2024, primarily due to increased headcount and expenses related to the SCN acquisition [11][23] Strategic Initiatives - The acquisition of the Sleep Center of Nevada has introduced new revenue streams, contributing $2.2 million in diagnostic sleep testing revenue and $1.3 million in treatment center revenue during Q3 2025 [4][23] - Vivos is implementing an updated sleep practice affiliation model to collaborate with sleep centers that prefer not to be acquired, allowing them to offer Vivos' diagnostic and treatment options [5][6] - The company is actively seeking similar management agreements in other major markets to expand its reach and service offerings [6] Market Outlook - Vivos anticipates significant local market growth potential in Las Vegas, with patient bookings extending into February 2026 as they work to enhance operations and capacity [2][4] - The company plans to continue adding new sleep optimization teams in 2026, which is expected to reduce cash burn and pave the way for profitable operations [3][11]

Core Viewpoint - Vivos Therapeutics, Inc. is set to release its third quarter 2025 financial results and will discuss strategic collaborations that may impact revenue growth and cash burn during a conference call scheduled for November 19, 2025 [1][2]. Company Overview - Vivos Therapeutics, Inc. specializes in medical devices and healthcare services for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [5]. - The company has developed proprietary treatments and diagnostic procedures, with its devices cleared by the FDA for various severity levels of OSA in both adults and children [5]. - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first for moderate to severe OSA in children [5]. Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [6]. - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for innovative solutions [6]. Strategic Initiatives - Vivos aims to enhance its market position through technology, education, and collaborations with sleep healthcare providers to better address OSA patients' needs [7]. - The company promotes The Vivos Method, a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [8].

Core Viewpoint - Vivos Therapeutics, Inc. has made a significant acquisition of The Sleep Center of Nevada, which is expected to enhance its revenue generation and patient demand for its obstructive sleep apnea (OSA) treatments. The company is transitioning its business model to focus on direct patient relationships and sleep center alliances [1][3]. Financial Performance - For the second quarter of 2025, Vivos reported revenue of $3.8 million, a decrease from $4.1 million in the same period of 2024. For the six months ended June 30, 2025, revenue was $6.8 million compared to $7.5 million in 2024 [4]. - Gross profit for the second quarter of 2025 was $2.1 million, down from $2.7 million in the second quarter of 2024. For the six months ended June 30, 2025, gross profit was $3.6 million compared to $4.6 million in 2024 [4]. - The gross margin declined to 55% in the second quarter of 2025 from 65% in the same period of 2024, attributed to pricing discounts and the transition to a new sales model [4]. - Operating expenses increased by 52% to $7.0 million in the second quarter of 2025, compared to $4.6 million in the same period of 2024, largely due to costs associated with the acquisition and integration of SCN [4]. Strategic Initiatives - The acquisition of The Sleep Center of Nevada marks a strategic shift in Vivos' sales and marketing approach, moving from a dentist-reliant model to a more comprehensive model that includes direct patient engagement [3]. - Vivos is also developing a new sleep practice management model to partner with sleep centers that are not interested in acquisition but want to offer Vivos' OSA diagnostic and treatment options [5][6]. - The company is actively seeking additional sleep center alliances or acquisitions to scale its new model, as demand at SCN locations has exceeded current capacity [3]. Market Context - OSA affects over 1 billion people globally, with a significant portion remaining undiagnosed. This presents a substantial market opportunity for innovative treatments that address the root causes of OSA [11]. - Vivos' proprietary treatments, including the Complete Airway Repositioning and Expansion (CARE) devices, are FDA-cleared for various severity levels of OSA, positioning the company favorably in the medical device market [10].

Core Viewpoint - Vivos Therapeutics, Inc. is set to release its second quarter 2025 financial results and will conduct a conference call to discuss these results and recent developments in the company [1][2][3] Company Overview - Vivos Therapeutics, Inc. specializes in developing and commercializing treatments for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [4] - The company’s devices are FDA-cleared for all severity levels of OSA in adults and moderate to severe OSA in children aged 6 to 17 [4] - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first for moderate to severe OSA in children [4] Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [5] - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for innovative solutions [5] Strategic Initiatives - Founded in 2016, Vivos aims to empower healthcare providers to better address the needs of OSA patients through innovative technology and collaborations [6] - The company promotes The Vivos Method, a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [7]